Zacks: Analysts Anticipate Clearside Biomedical Inc (NASDAQ:CLSD) to Post -$0.06 EPS

Equities analysts forecast that Clearside Biomedical Inc (NASDAQ:CLSD) will report earnings per share (EPS) of ($0.06) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clearside Biomedical’s earnings. The highest EPS estimate is $0.00 and the lowest is ($0.16). Clearside Biomedical posted earnings of ($0.68) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 91.2%. The firm is scheduled to announce its next earnings report on Tuesday, March 10th.

According to Zacks, analysts expect that Clearside Biomedical will report full-year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.71). For the next year, analysts anticipate that the firm will post earnings of ($0.45) per share, with EPS estimates ranging from ($0.59) to ($0.22). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.05 million. Clearside Biomedical had a negative net margin of 18,893.49% and a negative return on equity of 316.25%.

Several equities analysts recently issued reports on CLSD shares. JMP Securities set a $3.00 price target on Clearside Biomedical and gave the company a “buy” rating in a research note on Thursday, August 22nd. ValuEngine lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Tuesday. Laidlaw downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Needham & Company LLC restated a “hold” rating on shares of Clearside Biomedical in a research note on Thursday, October 31st. Finally, Zacks Investment Research cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Clearside Biomedical has a consensus rating of “Hold” and an average target price of $2.33.

NASDAQ:CLSD opened at $1.72 on Friday. The firm’s 50-day moving average is $1.12 and its 200-day moving average is $1.01. The company has a market cap of $59.26 million, a price-to-earnings ratio of -0.64 and a beta of -0.27. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.22 and a current ratio of 2.22. Clearside Biomedical has a 52-week low of $0.56 and a 52-week high of $1.90.

A number of institutional investors have recently modified their holdings of CLSD. Jane Street Group LLC acquired a new position in shares of Clearside Biomedical in the second quarter valued at about $98,000. Vanguard Group Inc. lifted its stake in Clearside Biomedical by 66.9% during the 2nd quarter. Vanguard Group Inc. now owns 924,485 shares of the company’s stock valued at $899,000 after acquiring an additional 370,690 shares during the period. A.R.T. Advisors LLC acquired a new stake in shares of Clearside Biomedical in the second quarter worth $95,000. Paloma Partners Management Co purchased a new position in shares of Clearside Biomedical during the second quarter worth $122,000. Finally, Millennium Management LLC raised its holdings in shares of Clearside Biomedical by 273.6% during the third quarter. Millennium Management LLC now owns 280,533 shares of the company’s stock worth $176,000 after purchasing an additional 205,444 shares during the last quarter. Institutional investors and hedge funds own 16.97% of the company’s stock.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

Further Reading: How is the Producer Price Index calculated?

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit